Handelsavisen
prelaunch
Companies ›Healthcare ›MPH.V
MP
MPH.V — TSX Venture Biotechnology & Medical Research

Mph.V

$1,07
Open in Charts → Attach watcher ⌖
— —
CAD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
11,2M CAD
P/E
—
EV / Rev
—
Div yield
—
Op margin
-23,9 %
ROE
-55,0 %
Net margin
-24,6 %
Debt / equity
0,07
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

MPH.V operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research activities.

Business. MPH.V operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research activities.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
-55,0 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning MPH.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to MPH.V. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    MPH.V operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research activities.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    MPH.V's capital structure is characterized by a low debt-to-equity ratio of 0.07, indicating a conservative leverage position. The company's liquidity is assessed as low, with a current ratio of 1.02 and negative operating cash flow of -560,000 CAD. The price-to-book ratio of 0.9 suggests the market values the company slightly below its book value.

    Profitability metrics for MPH.V show a return on equity of -0.5498 and a return on assets of -0.2845, both significantly below the industry norms. The company reported a net loss of 7,097,000 CAD, with an operating loss of 6,888,000 CAD, indicating challenges in achieving profitability.

    Geographic and segment exposure data for MPH.V is not available in the provided information. However, the company's revenue concentration and segment performance are not disclosed, making it difficult to assess diversification risks.

    The growth trajectory for MPH.V is uncertain, with a reported revenue of 28,855,000 CAD. The company's recent performance shows a decline from the analyst estimate of 11,610,000 CAD, suggesting potential operational or market challenges.

    Risk factors for MPH.V include low liquidity and the potential for dilution, although no immediate filing-based flags were detected. The company's negative operating cash flow and net loss highlight financial risks that could affect its stability.

    Recent events and filings for MPH.V do not show any significant developments that would impact its financial position or strategic direction. The company's financial statements and disclosures do not indicate any major changes in its operations or capital structure.

    Key takeaways
    • MPH.V has a conservative capital structure with a low debt-to-equity ratio of 0.07.
    • The company is currently unprofitable, with a return on equity of -0.5498 and a return on assets of -0.2845.
    • Liquidity is a concern, as indicated by a low current ratio of 1.02 and negative operating cash flow.
    • Revenue performance has declined from the analyst estimate, suggesting potential operational or market challenges.
    • There are no immediate filing-based liquidity or dilution flags, but the company's financial risks remain significant.
    • **margin_outlook_rationale**: The company's negative operating income and net loss indicate a deteriorating margin outlook driven by operational inefficiencies.
    • **rd_outlook_rationale**: No specific information is available to assess the research and development outlook for MPH.V.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $1,07
    Market cap
    $11.6M
    Enterprise valueⓘ
    $8.6M
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    0.9x
    P / Tangible bookⓘ
    0.9x
    Tangible book
    $12.9M
    Net cashⓘ
    $2.9M
    Current ratioⓘ
    1.0
    Debt / equityⓘ
    0.1
    ROAⓘ
    -28.4%
    ROEⓘ
    -55.0%
    Cash conversionⓘ
    8.0%
    CapEx / revenueⓘ
    0.0%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-23,9 %Above median
    Net Margin-24,6 %Above median
    ROE-55,0 %Bottom quartile
    Capex / Rev0,0 %Above P75
    D/E0,07Below median
    Cash Conv0,08Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    Source documents
    • MPH.V Market data — financials · 2026-05-28
    • Medicure Inc Market data — analyst estimates · 2026-05-28

    Ownership & reference

    Leadership

    • Albert D. FriesenChairman of the Board, Chief Executive Officer

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    MPH.VCanonical
    TSX Venture · CAD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage